Anti-Human CD274 Recombinant Antibody (Durvalumab) (CAT#: TAB-417CQ)
Recombinant monoclonal antibody to CD274. Durvalumab is a human monoclonal antibody that can be potentially used in the treatment of Cancers, non-small cell lung (NSCLC), Solid tumors, bladder, urothelial.
Specific Inquiry
FuncS
Figure 1 Monalizumab and Durvalumab Unleash NK and CD8 + T Cell Function In Vitro.
NK cells were co-cultured with K562 or K562 cells expressing HLA-E in the presence or absence of monalizumab. The frequencies of CD107-positive NK cells are shown. Box and whiskers plot, with the means indicated by crosses. N = 8. The whiskers are drawn down to the 25th percentile minus 1.5 times IQR (interquartile range) and up to the 75th percentile plus 1.5 times IQR. Friedman analysis followed by Dunn's multiple comparisons test. **p = 0.006; ***p = 0.0001.
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T.,... & Rossi, B. (2018). Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell, 175(7), 1731-1743.
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- IgG1, κ
- Specificity
- Human CD274
- Species Reactivity
- Human
- Applications
- ELISA, IHC, FC, IP, IF, Inhib, FuncS
- Conjugate
- Unconjugated
- Trade name
- Imfinzi
- CAS
- 1428935-60-7
- Generic Name
- Durvalumab
- UNII
- 28X28X9OKV
- Related Disease
- Cancers, non-small cell lung (NSCLC), Solid tumors, bladder, urothelial
Product Property
- Purity
- > 95% as determined by SDS-PAGE
- Storage
- Store at -20°C for long-term storage. Avoid freeze/thaw cycles.
Applications
- Application Notes
- The CD274 antibody has been reported in applications of ELISA, IHC, FC, IP, IF, Inhib, FuncS.
Target
- Alternative Names
- Programmed cell death 1 ligand 1; B7H1; B7-H1; PDL1; PD-L1; PDCD1L1; B7 homolog 1; B7 homologue 1
- Gene ID
- 29126
- UniProt ID
- Q9NZQ7
Related Resources
Please refer to Durvalumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Durvalumab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Durvalumab"
Afuco™ Anti-CD274 ADCC Recombinant Antibody (Durvalumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD274. Durvalumab is a human monoclonal antibody that can be potentially used in the treatment of Cancers, non-small cell lung (NSCLC), Solid tumors, bladder, urothelial.
See other products for "Cd274"
Select a product category from the dropdown menu below to view related products.
Please select product type
Single-domain Antibody
Human Antibody
Humanized Antibody
Chimeric Antibody
Mouse Antibody
Neutralizing Antibody
Blocking Antibody
Rabbit Monoclonal Antibody
Recombinant Antibody
Fab Fragment Antibody
ADCC Enhanced Antibody
scFv Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NAB-305-sdAb | Recombinant Anti-Mouse Cd274 VHH Single Domain Antibody | IHC, IP, FC, Neut, FUNC | Llama VHH |
| NBD-0065-YJ-VHH | Camelid Anti-CD274 Recombinant Single Domain Antibody (NBD-0065-YJ-VHH) | ELISA | Camelid VHH |
| NBD-0066-YJ-VHH | Camelid Anti-CD274 Recombinant Single Domain Antibody (NBD-0066-YJ-VHH) | ELISA, Inihb | Camelid VHH |
| NBD-0067-YJ-VHH | Camelid Anti-CD274 Recombinant Single Domain Antibody (NBD-0067-YJ-VHH) | ELISA, FC | Camelid VHH |
| NBD-0068-YJ-VHH | Camelid Anti-CD274 Recombinant Single Domain Antibody (NBD-0068-YJ-VHH) | ELISA, FC | Camelid VHH |
Customer Reviews and Q&As
Customer Review
Q&As
-
Ideal for Durvalumab Studies
The Durvalumab has been excellent for our PD-L1 studies. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time. -
Effective in Immunoassays
We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for PD-L1 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab. -
Consistent and High-Quality
This antibody has proven to be consistent and high-quality in our assays. The reproducible results and strong affinity for PD-L1 have significantly improved our experiments, making it a crucial part of our research toolkit. The consistent performance has greatly enhanced our data quality.
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-417CQ, RRID: AB_3111930)
Copy citation
Popular products with customers
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: WB, IF, IP, Neut, FuncS, ELISA, FC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: FC, FuncS, IHC, ELISA
![Figure 1 Anti-Human CD19 Recombinant Antibody Fab Fragment [TAB-1611CL-F(E)] in SDS-PAGE](https://img.creativebiolabs.net/productimages/COA-TAB-1611CL-F(E)-1.png)
Application: Depletion, FuncS
Application: ELISA, FuncS, IHC, IF, FC, ADCC
Application: ELISA, IHC, IF, IP, FC, FuncS
Application: ELISA, PD, Activ, PK, Stim
Application: ELISA, WB, Microarray, Block
-1.png)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
